Fig. 2: Adjusted vaccine effectiveness (VE) and relative vaccine effectiveness (rVE) of mRNA-1273 against infection with omicron subvariants by time since 3rd dose vaccination.

Adjusted VE of three doses of mRNA-1273 and adjusted rVE of three versus two doses of mRNA-1273 and their 95% confidence intervals against infection with SARS-CoV-2 omicron subvariants. Sample size for each analysis equals the number of three-dose vaccinated divided by the percentage of three-dose vaccinated. Symbols represent the adjusted vaccine effectiveness or adjusted relative vaccine effectiveness. ^aWhen the OR or its 95% CI was >1, the VE/rVE or its 95% CI was transformed as ([1/OR] – 1) × 100. ^bAdjusted for age, sex, race/ethnicity, month of specimen collection, history of SARS-CoV-2 infection, history of SARS-CoV-2 molecular test, number of outpatient and virtual visits, medical center area, and time between second dose and specimen collection date (for three-dose versus two-dose models only). ^cMedical center area removed from adjustment set in three-dose versus two-dose models due to lack of model convergence. ^dBA.2 excluding BA.2.12.1. ^eMedical center area removed from adjustment set in three-dose versus unvaccinated models due to lack of model convergence. CI confidence interval, OR odds ratio, rVE relative vaccine effectiveness, VE vaccine effectiveness.